Update of the results of the phase 2 CREST trial, bortezomib in refractory or relapsed multiple myeloma

被引：0
|
作者：
Wemeau, Mathieu
Leleu, Xavier
机构：
来源：
HEMATOLOGIE | 2009年 / 15卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [1] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [2] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [3] VIM: the results of a phase 1/2 trial of bortezomib, idarubicin and melphalan in relapsed or refractory multiple myeloma
    Boyd, K.
    Davies, F.
    Morgan, G.
    Bonner, A.
    Conneely, L.
    Kabir, M.
    Machell, G.
    Pawlyn, C.
    Saso, R.
    Smith, L.
    Strong, E.
    Kaiser, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 118 - 118
  • [4] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Reeder, Craig B.
    Roy, Vivek
    Halvorson, Alese E.
    Buadi, Francis
    Gertz, Morie A.
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Thompson, Melanie A.
    Crawley, Jamie
    Kapoor, Prashant
    Mikhael, Joseph
    Stewart, Keith
    Hayman, Suzanne R.
    Hwa, Yi L.
    Gonsalves, Wilson
    Witzig, Thomas E.
    Ailawadhi, Sikander
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Rivera, Candido E.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2016, 128 (20) : 2415 - 2422
  • [5] Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Banwait, Ranjit
    Azab, Abdel Kareem
    Phong Quang
    Laubach, Jacob P.
    Donovan, Amanda
    Bagshaw, Meghan
    Armand, Philippe
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 817 - 818
  • [6] Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene
    Azab, Abdel Kareem A.
    Laubach, Jacob P.
    Banwait, Ranjit
    Rourke, Meghan
    Quang, Phong
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Sam, Amy
    Still, Eric
    Morgan, Brittany
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 809 - 810
  • [7] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (10) : 1461 - 1469
  • [8] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Szatrowski, T.
    Kaplita, S.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
  • [9] Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
    Richardson, Paul G.
    Bensinger, William I.
    Huff, Carol Ann
    Costello, Caitlin L.
    Lendvai, Nikoletta
    Berdeja, Jesus G.
    Anderson, Larry D., Jr.
    Siegel, David S.
    Lebovic, Daniel
    Jagannath, Sundar
    Laubach, Jacob P.
    Stockerl-Goldstein, Keith E.
    Kwei, Long
    Clow, Fong
    Elias, Laurence
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Vij, Ravi
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 821 - 830
  • [10] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
12345